Intracranial Meningioma Clinical Trial
Official title:
Cognition-preserving Brain Irradiation for Treating Patients With Intracranial Meningioma in the Era of Modern Radiotherapeutic Techniques Including Proton Beam Therapy - a Prospective Study Focusing on Radiological Outcomes and Neurocognitive Endpoints
【Background】For cranial-irradiation-naive patients with intracranial meningiomas at risk of local recurrence, the administration of conformal cranial radiotherapy can enhance tumor control in the current era of modern radiotherapeutic techniques. Life expectancy in patients with intracranial meningiomas, particularly non-malignant meningiomas (WHO grade I and II) is essentially similar to people of general population. However, RT-related neurocognitive function (NCF) sequelae are potentially and seriously a concern which should not be ignored. In terms of the natural course of cranial irradiation-induced NCF decline, it might vary considerably according to the specific domains which are selected to be measured. Early neurocognitive decline principally involves impairments of episodic memory, which is significantly associated with functions of the hippocampus. Additionally, the extent of changes in hippocampal volume after local irradiation may be associated with the hippocampal dosimetry. This study thus aims to investigate the potential cause-effect relationship between the hippocampal dosimetry and radiological outcomes represented by the volumetric changes regarding the contralateral hippocampus; furthermore, the correlation between radiological outcomes and neurocognitive endpoints will be examined and clarified. 【Methods】Patients with cranial-RT-naive intracranial meningiomas may be eligible and therefore enrolled in this prospective study addressing both radiological outcomes and neurocognitive endpoints. All eligible and recruited patients should receive baseline volumetric brain MRI examination and baseline neurobehavioral assessment. Subsequently, conformal cranial irradiation in the era of modern radiotherapeutic techniques (including hypofractionated stereotactic radiotherapy, proton beam therapy volumetric modulated arc therapy) will be utilized in order to reduce the dose irradiating the contralateral hippocampus and other relevant organs at risk. The prescribed dose schemes for treating patients with intracranial meningioma depend on the decision of the radiation oncologist in charge and follow the treatment guidelines at our cancer center. Accordingly, a battery of neurocognitive measures, which includes 9 standardized neuropsychological tests categorized into 5 NCF domains (e.g., executive functions, verbal & non-verbal memory, working memory, psychomotor speed, and amygdala-related emotion recognition), is used to evaluate neurocognitive performances longitudinally for our registered patients. There will be two co-primary outcome measures in the current study. The main primary outcome will be the correlation between the mean hippocampal dose and the extent of change in hippocampal volume at 6 months after the course of cranial RT. The other primary endpoint will be 6-month cognitive-deterioration-free survival. 【Expected Results】This prospective observational cohort study aims to explore and investigate the cause-effect relationship between the hippocampal dosimetry (i.e., mean dose irradiating the hippocampus, particularly the one contralateral to the lateralization of intracranial meningioma) and the extent of hippocampal atrophy signifying one of the measures regarding radiological outcomes. Simultaneously, predefined standardized neurocognitive outcome measures such as hippocampus-related memory functions and amygdala-related emotion recognition will be obtained prospectively and longitudinally in order to examine whether any meaningfully significant correlation exists between the above radiological outcome measures and neurocognitive endpoints. The mutual associations among hippocampal dosimetry, radiological outcomes including the MRI-delineated hippocampal volume, and neurocognitive endpoints including hippocampus-related verbal/non-verbal memory functions will be examined thoroughly.
Status | Not yet recruiting |
Enrollment | 74 |
Est. completion date | July 31, 2026 |
Est. primary completion date | July 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Patients with clinically or pathologically-confirmed intracranial non-malignant meningiomas who are at least 18 years old, referred for arranging conformal radiotherapy - A Fair/good performance status superior to Eastern Cooperative Group (ECOG) of 2 or an acceptable performance status of Karnofsky Score (KPS) at least 70 Exclusion Criteria: - History of prior radiotherapy delivered to brain/head region for any reason, including stereotactic radiosurgery - Patients with malignant meningiomas diagnosed pathologically (WHO grade III) - Patients with presumed clinical target volume (CTV) encompassing bilateral peri-hippocampal regions within 5 mm away from the adjacent periphery of the hippocampus - Patients whose quality of volumetric MRI fails to meet the minimal requirements for physicians to delineate the hippocampal contouring (i.e., slice thickness > 2mm) |
Country | Name | City | State |
---|---|---|---|
Taiwan | Chang Gung Memorial Hospital | Taoyuan |
Lead Sponsor | Collaborator |
---|---|
Chang Gung Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Longitudinal changes in the volumes of organs at risk including the hippocampus | Longitudinal changes in the volumes (cc) of the left hippocampus, right hippocampus, left amygdala, right amygdala, left thalamus, right thalamus, and so on based on volumetric MR imaging examinations | baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months | |
Secondary | Change in verbal memory function | Change in verbal memory function related to left hippocampus from baseline to 4 months after cognition-preserving cranial RT | baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months | |
Secondary | Change in non-verbal memory learning | Change in non-verbal memory learning associated with right hippocampus from baseline to 4 months after cognition-preserving brain RT | baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months | |
Secondary | Change in executive function | Change in executive function related to hippocampus from baseline to 4 months after cognition-preserving cranial RT.
Concerning the domain of executive functions generally dominated by the frontal lobes, the Modified Card Sorting Test is employed to assess both conceptual formation and mental shifting which have been documented to be the major components of executive functions. |
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months | |
Secondary | Change in emotion memory task | Change in emotion memory tasks associated with the amygdala from baseline to 4 months after cognition-reserving cranial irradiation.
For evaluate and quantify the cognitive function of amygdala, the NCF test tailored to the emotional recognition task will be used and patients' performances will be assessed using the commercialized and computerized test included in Cambridge Cognition® package. |
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months | |
Secondary | Change in working memory | Change in working memory related to hippocampus from baseline to 4 months after cognition-preserving cranial RT.
Working memory includes executive functions and psychomotor speed. The neurocognitive outcome of verbal working memory was determined by the Digit Span Subtest (DS) and Spatial Span (SSP) of the Wechsler Adult Intelligence Scale- 3rd edition (WAIS-III®). In order to indicate patients' performance on the psychomotor speed, we make use of Psychomotor Speed Index (PSI), which is derived from the composite score of Digit Symbol Coding Subtest (DSS) and Symbol Searching Subtest (SS) of the WAIS-III®. |
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months | |
Secondary | Longitudinal changes in the imaging biomarkers | Longitudinal changes in the imaging biomarkers from DTI imaging | baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months | |
Secondary | Longitudinal changes in the fractional anisotropy | Longitudinal changes in the fractional anisotropy (FA, unitless index between 0 and 1) from DTI imaging | baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months | |
Secondary | Trajectories in the imaging biomarker | Trajectories in the imaging biomarker, mean diffusivity (MD, mm squared/second) based on DTI imaging | baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03180268 -
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
|
Phase 3 | |
Terminated |
NCT00972335 -
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
|
Phase 2 | |
Recruiting |
NCT02523014 -
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
|
Phase 2 | |
Active, not recruiting |
NCT02974127 -
Multisession Radiosurgery in Large Meningiomas
|
||
Not yet recruiting |
NCT02084927 -
Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery
|
Phase 1 |